iShares Biotechnology ETF (NASDAQ:IBB) Stock Price Cross Below 50 Day Moving Average – Here’s What Happened

iShares Biotechnology ETF (NASDAQ:IBB – Get Free Report)’s share price passed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $208.87 and traded as low as $207.62. iShares Biotechnology ETF shares last traded at $207.98, with a volume of 2,289,353 shares trading hands.

iShares Biotechnology ETF Stock Performance

The stock’s 50-day moving average is $208.87 and its 200-day moving average is $187.08.

iShares Biotechnology ETF Cuts Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 18th. Shareholders of record on Tuesday, September 15th were paid a $0.0112 dividend. This represents a $0.04 annualized dividend and a yield of 0.0%. This is a decrease from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238. The ex-dividend date of this dividend was Tuesday, September 15th.

Hedge Funds Weigh In On iShares Biotechnology ETF

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. boosted its holdings in iShares Biotechnology ETF by 188.8% in the third quarter. Goldman Sachs Group Inc. now owns 3,397,078 shares of the financial services provider’s stock worth $715,187,000 after acquiring an additional 2,220,901 shares in the last quarter. WCG Wealth Advisors LLC bought a new stake in shares of iShares Biotechnology ETF during the third quarter valued at approximately $1,542,000. Waterloo Capital L.P. bought a new stake in shares of iShares Biotechnology ETF during the third quarter valued at approximately $958,000. Cetera Investment Advisers raised its position in shares of iShares Biotechnology ETF by 8.2% during the third quarter. Cetera Investment Advisers now owns 125,262 shares of the financial services provider’s stock worth $26,371,000 after purchasing an additional 9,458 shares during the period. Finally, Pathstone Holdings LLC raised its position in shares of iShares Biotechnology ETF by 57.2% during the third quarter. Pathstone Holdings LLC now owns 12,687 shares of the financial services provider’s stock worth $2,685,000 after purchasing an additional 4,616 shares during the period. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Company Profile

(Get Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Articles

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.